Redmond Asset Management’s TherapeuticsMD TXMD Stock Holding History

Redmond Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,048	Closed	-$672K	–	171
2018 Q3	$672K	Buy	2,048 +22	+1%	+$6.74K	0.26%	107
2018 Q2	$632K	Hold	2,026	–	–	0.27%	102
2018 Q1	$493K	Buy	2,026 +24	+1%	+$6.73K	0.22%	117
2017 Q4	$605K	Hold	2,002	–	–	0.26%	104
2017 Q3	$530K	Hold	2,002	–	–	0.24%	114
2017 Q2	$528K	Buy	2,002 +10	+0.5%	+$2.5K	0.25%	112
2017 Q1	$717K	Buy	1,992 +21	+1%	+$6.5K	0.37%	91
2016 Q4	$569K	Buy	+1,971	New	+$611K	0.26%	113

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Redmond Asset Management's TXMD Position: Q4 2018 in Review

Redmond Asset Management sold out of TherapeuticsMD (TXMD) in Q4 2018, closing a stake of 2,048 shares — an estimated $672K sold.

Redmond Asset Management first reported a position in TXMD in Q4 2016 and held it in 8 quarters. The position peaked at $717K in Q1 2017. 140 funds tracked by Wall St. Rank hold TXMD as of Q4 2018.

Redmond Asset Management reported no remaining TherapeuticsMD position as of Q4 2018 after selling out during the quarter.
Redmond Asset Management sold 2,048 TherapeuticsMD shares in Q4 2018, an estimated $672K.
Redmond Asset Management first reported a position in TherapeuticsMD in Q4 2016 and held it in 8 quarters.
Redmond Asset Management's TherapeuticsMD position peaked at $717K in Q1 2017.
140 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2018.

Based on Redmond Asset Management's 13F filing for Q4 2018, filed 6 Feb 2019.